Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge

British Journal of Pharmacology

Volumn 132, Issue 7, 2001, Pages 1565-1573

  Gretzer, Britta ^a   Maricic, Nenad ^a   Respondek, Michael ^a   Schuligoi, Rufina ^b   Peskar, Brigitta M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cyclo oxygenase 1; Cyclo oxygenase 2; DFU; Gastric damage; Non steroidal anti inflammatory drugs; Platelet thromboxane; Rofecoxib; SC 560

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; INDOMETACIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; ROFECOXIB; THROMBOXANE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ICOSANOID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; STOMACH MUCOSA INJURY; STOMACH PH; STOMACH PROTECTION;

EID: 0035067053     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703955     Document Type: Article

References (39)

1. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
2. Immunohistochemical distribution of constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2) in benign and malignant gastric mucosa
3. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: Role of cyclooxygenase-2
4. Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia; role in resistance to damage
5. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions
6. Selective cyclooxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach
7. Effect of SC-560, a selective cyclooxygenase (COX)-1 inhibitor, and its modification by COX-2 inhibition in the rat stomach
8. The macula densa: Recent developments
9. Human cyclooxygenase-2 cDNA
10. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach
11. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
12. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
13. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
14. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
15. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
16. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex
17. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach
18. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic
19. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
20. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection
21. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
22. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
23. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2
24. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
25. Prostaglandins and bone: Physiology and pathophysiology
26. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases
27. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
28. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
29. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis
30. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
31. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
32. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
33. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
34. Pharmacological analysis of cyclooxygenase-1 in inflammation
35. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
36. Expression of cyclooxygenase-1 and -2 (COX-1 and COX-2) in normal gastric mucosa. Effect of antacid (hydrotalcit) treatment
37. New insights into the mode of action of anti-inflammatory drugs
38. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
39. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis